home / stock / ogen / ogen quote
Last: | $1.34 |
---|---|
Change Percent: | -6.48% |
Open: | $1.15 |
Close: | $1.34 |
High: | $1.55 |
Low: | $1.13 |
Volume: | 584,005 |
Last Trade Date Time: | 05/07/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.34 | $1.15 | $1.34 | $1.55 | $1.13 | 584,005 | 05-07-2024 |
$1.08 | $1.1 | $1.08 | $1.1799 | $1.0601 | 36,920 | 05-06-2024 |
$1.07 | $1.06 | $1.07 | $1.07 | $1.0327 | 15,688 | 05-03-2024 |
$1.0501 | $1.02 | $1.0501 | $1.07 | $1.02 | 11,185 | 05-02-2024 |
$1.02 | $1.01 | $1.02 | $1.04 | $1.01 | 9,040 | 05-01-2024 |
$1.035 | $1.05 | $1.035 | $1.06 | $1.02 | 8,221 | 04-30-2024 |
$1.01 | $1.07 | $1.01 | $1.07 | $1 | 35,440 | 04-29-2024 |
$1.03 | $1.07 | $1.03 | $1.08 | $1.01 | 43,816 | 04-26-2024 |
$1.06 | $1.1 | $1.06 | $1.15 | $1.049 | 61,782 | 04-25-2024 |
$1.09 | $1.11 | $1.09 | $1.11 | $1.05 | 9,186 | 04-24-2024 |
$1.09 | $1.07 | $1.09 | $1.09 | $1.03 | 18,832 | 04-23-2024 |
$1.06 | $1.1 | $1.06 | $1.13 | $1.04 | 15,021 | 04-22-2024 |
$1.13 | $1.16 | $1.13 | $1.22 | $1.13 | 15,554 | 04-19-2024 |
$1.13 | $1.1328 | $1.13 | $1.16 | $1.11 | 23,459 | 04-18-2024 |
$1.08 | $1.02 | $1.08 | $1.135 | $1.015 | 71,803 | 04-17-2024 |
$1.08 | $1.2 | $1.08 | $1.24 | $1.05 | 124,079 | 04-16-2024 |
$1.22 | $1.19 | $1.22 | $1.3 | $1.15 | 41,814 | 04-15-2024 |
$1.23 | $1.27 | $1.23 | $1.27 | $1.17 | 19,913 | 04-12-2024 |
$1.23 | $1.24 | $1.23 | $1.29 | $1.1761 | 47,863 | 04-11-2024 |
$1.2 | $1.34 | $1.2 | $1.42 | $1.17 | 168,695 | 04-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
SARASOTA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneer in developing innovative intranasal pharmaceuticals for neurological disorders, today announced a partnership with Avance Clinical, a leading Contract Research Organization (CRO), to conduct a Phase ...
Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) dated April ...
Oragenics, Inc. (the “Company”) (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has filed its annual report on March 29, 2024. The Company is pleased to report it has execu...